Skip to main content
icon for FDA moves BPC-157 to Category 1 by…?
Politics·Health

FDA moves BPC-157 to Category 1 by…?

icon for FDA moves BPC-157 to Category 1 by…?
Politics·Health

FDA moves BPC-157 to Category 1 by…?

NEW
Aug 31, 2026
Polymarket

$3,370 Vol.

Polymarket

August 31, 2026

$1,654 Vol.

6%

December 31, 2026

$1,716 Vol.

50%

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23, 2026, 8-6 advisory committee vote recommending BPC-157 for the 503A Bulk Drug Substances List marked the clearest recent catalyst for trader positioning on reclassification timelines. That non-binding outcome followed the substance’s April 2026 removal from interim Category 2 and occurred despite FDA staff concerns over limited human data, immunogenicity risks, and characterization gaps for proposed routes of administration. Formal inclusion on Category 1 still requires notice-and-comment rulemaking, a process that historically spans many months and is not guaranteed to follow the panel’s recommendation. With the current date in late August 2026, the near-term probability hinges on whether the agency accelerates or defers action ahead of scheduled public-comment periods and any follow-on committee reviews. Market pricing therefore reflects both the political momentum behind expanded compounding access and the procedural barriers that typically delay final determinations well beyond single advisory votes.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$3,370
End Date
Jan 1, 2027
Market Opened
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23, 2026, 8-6 advisory committee vote recommending BPC-157 for the 503A Bulk Drug Substances List marked the clearest recent catalyst for trader positioning on reclassification timelines. That non-binding outcome followed the substance’s April 2026 removal from interim Category 2 and occurred despite FDA staff concerns over limited human data, immunogenicity risks, and characterization gaps for proposed routes of administration. Formal inclusion on Category 1 still requires notice-and-comment rulemaking, a process that historically spans many months and is not guaranteed to follow the panel’s recommendation. With the current date in late August 2026, the near-term probability hinges on whether the agency accelerates or defers action ahead of scheduled public-comment periods and any follow-on committee reviews. Market pricing therefore reflects both the political momentum behind expanded compounding access and the procedural barriers that typically delay final determinations well beyond single advisory votes.

This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.

A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.

Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.

A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.

The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$3,370
End Date
Jan 1, 2027
Market Opened
Jun 22, 2026, 10:10 PM ET

Resolver

0x65070BE91...
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”. A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify. Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date. A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify. The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.

Related

icon for Will Heidi Overton be confirmed as FDA Commissioner by December 31?

Will Heidi Overton be confirmed as FDA Commissioner by December 31?

52%
icon for Weed rescheduled by December 31?

Weed rescheduled by December 31?

18%
icon for Skin cancer vaccine BLA submitted by June 30, 2027?

Skin cancer vaccine BLA submitted by June 30, 2027?

88%

Beware of external links.

Frequently Asked Questions

"FDA moves BPC-157 to Category 1 by…?" is a prediction market on Polymarket with 2 possible outcomes where traders buy and sell shares based on what they believe will happen. The current leading outcome is "December 31, 2026" at 50%, followed by "August 31, 2026" at 6%. Prices reflect real-time crowd-sourced probabilities. For example, a share priced at 50¢ implies that the market collectively assigns a 50% chance to that outcome. These odds shift continuously as traders react to new developments and information. Shares in the correct outcome are redeemable for $1 each upon market resolution.

"FDA moves BPC-157 to Category 1 by…?" is a newly created market on Polymarket, launched on Jun 22, 2026. As an early market, this is your opportunity to be among the first traders to set the odds and establish the market's initial price signals. You can also bookmark this page to track volume and trading activity as the market gains traction over time.

To trade on "FDA moves BPC-157 to Category 1 by…?," browse the 2 available outcomes listed on this page. Each outcome displays a current price representing the market's implied probability. To take a position, select the outcome you believe is most likely, choose "Yes" to trade in favor of it or "No" to trade against it, enter your amount, and click "Trade." If your chosen outcome is correct when the market resolves, your "Yes" shares pay out $1 each. If it's incorrect, they pay out $0. You can also sell your shares at any time before resolution if you want to lock in a profit or cut a loss.

The current frontrunner for "FDA moves BPC-157 to Category 1 by…?" is "December 31, 2026" at 50%, meaning the market assigns a 50% chance to that outcome. The next closest outcome is "August 31, 2026" at 6%. These odds update in real-time as traders buy and sell shares, so they reflect the latest collective view of what's most likely to happen. Check back frequently or bookmark this page to follow how the odds shift as new information emerges.

The resolution rules for "FDA moves BPC-157 to Category 1 by…?" define exactly what needs to happen for each outcome to be declared a winner — including the official data sources used to determine the result. You can review the complete resolution criteria in the "Rules" section on this page above the comments. We recommend reading the rules carefully before trading, as they specify the precise conditions, edge cases, and sources that govern how this market is settled.